Please use this identifier to cite or link to this item:
Title: Distinctive Expression and Amplification of Genes at 11q13 in Relation to HPV Status with Impact on Survival in Head and Neck Cancer Patients
Author: Hermida Prado, Francisco
Menéndez, Sofía T.
Albornoz Afanasiev, Pablo
Granda Diaz, Rocío
Álvarez Teijeiro, Saúl
Villaronga, M. Ángeles
Allonca, Eva
Alonso Duran, Laura
León, Xavier
Alemany i Vilches, Laia
Mena Cervigón, Marisa
Rio Ibisate, Nagore del
Astudillo, Aurora
Rodriguez, René
Rodrigo, Juan P.
García Pedrero, Juana M.
Keywords: Papil·lomavirus
Càncer de coll
Càncer de cap
Neck cancer
Head cancer
Issue Date: 1-Dec-2018
Publisher: MDPI
Abstract: Clear differences have been established between head and neck squamous cell carcinomas (HNSCC) depending on human papillomavirus (HPV) infection status. This study specifically investigated the status of the CTTN, CCND1 and ANO1 genes mapping at the 11q13 amplicon in relation to the HPV status in HNSCC patients. CTTN, CCND1 and ANO1 protein expression and gene amplification were respectively analyzed by immunohistochemistry and real-time PCR in a homogeneous cohort of 392 surgically treated HNSCC patients. The results were further confirmed using an independent cohort of 279 HNSCC patients from The Cancer Genome Atlas (TCGA). The impact on patient survival was also evaluated. CTTN, CCND1 and ANO1 gene amplification and protein expression were frequent in HPV-negative tumors, while absent or rare in HPV-positive tumors. Using an independent validation cohort of 279 HNSCC patients, we consistently found that these three genes were frequently co-amplified (28%) and overexpressed (39-46%) in HPV-negative tumors, whereas almost absent in HPV-positive tumors. Remarkably, these alterations (in particular CTTN and ANO1 overexpression) were associated with poor prognosis. Taken together, the distinctive expression and amplification of these genes could cooperatively contribute to the differences in prognosis and clinical outcome between HPV-positive and HPV-negative tumors. These findings could serve as the basis to design more personalized therapeutic strategies for HNSCC patients.
Note: Reproducció del document publicat a:
It is part of: Journal of Clinical Medicine, 2018, vol. 7, num. 12
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Hermida-PradoF.pdf2.36 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons